Polypharmacology Should Be the Rule, Not the Exception — Single-Target Drugs Are an Intellectual Crutch

The "one drug, one target" paradigm has dominated pharma since Paul Ehrlich's magic bullet concept. It's elegant. It's simple. And it's wrong for most complex diseases.

Cancer, neurodegeneration, diabetes, and psychiatric disorders are network diseases — they involve dysregulation of multiple interconnected pathways. A single-target drug hits one node while the network reroutes around it. This is why cancer develops resistance, why antidepressants have 30-50% non-response rates, and why Alzheimer's drugs targeting amyloid alone have failed.

Hypothesis: Rationally designed multi-target drugs (polypharmacology) will show superior outcomes to combination therapy in network diseases because they achieve coordinated pathway modulation in every cell, whereas combinations have variable pharmacokinetics across tissues. Designed polypharmacology will become the default approach for complex diseases by 2035.

Prediction: A rationally designed dual-target kinase inhibitor will show >20% improved progression-free survival over the corresponding combination of two single-target inhibitors in a Phase III oncology trial, due to more uniform target coverage.